PubMed HealthSearch

Biomedical subjects

J Drexler

Publications and source records attributed to J Drexler.

At least 19 recordsLinked to original sources

Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain.

In normal antigen-presenting cells, newly synthesized major histocompatibility complex (MHC) class II molecules associate with the invariant chain (Ii) glycoprotein in the endoplasmic reticulum (ER). They are loaded with peptides only after proteolytic removal of the Ii in post-Golgi endocytic vesicles. Since the Ii inhibits peptide binding to MHC class II molecules, this association could protect MHC class II molecules from being loaded with endogenous peptides early after biosynthesis. If this were an important function of the Ii in vivo, MHC class II molecules synthesized in cells lacking the Ii should be loaded efficiently with short endogenous peptides in the ER; such peptides are known to be present there due to TAP-mediated import from the cytosol. To examine this possibility, we have studied peptide loading in HeLa transfectants expressing murine H-2Ak MHC class II molecules either alone or together with an excess of Ii. Endogenous peptides could readily be extracted from conformationally intact Ak alpha beta dimers of biosynthetically labeled Ii+ cells, whereas peptide loading was greatly (> 95%) diminished in the absence of Ii. Significant amounts of sodium dodecyl sulfate-(SDS) stable 55-kDa peptide: Ak complexes were only found in the Ii+ transfectants. In the absence of Ii, the MHC class II molecules instead formed stable complexes with long (20 and 50 kDa) polypeptides. Known Ak-binding peptides bound stably to Ak molecules on Ii- cells, could be co-purified with them, and were resistant to release in SDS, suggesting that poor recovery of endogenous peptides was not due to decreased stability of Ak:peptide complexes in the absence of Ii. We conclude that protection of MHC class II molecules from endogenous short peptides does not appear to be a quantitatively important function of the Ii molecule, because peptide loading is inefficient in its absence.

Antigens, Differentiation, B-Lymphocyte

Epitope-specific enhancement of antigen presentation by invariant chain.

The MHC class II-associated invariant chain (Ii) is involved in the intracellular sorting of class II molecules to the endocytic pathway where peptides from processed exogenous antigens are bound, and thereby Ii is thought to enhance antigen presentation. Here we demonstrate that presentation of only one out of five epitopes of a given antigen is augmented by Ii. We have compared the presentation of five different epitopes derived from hen egg white lysozyme (HEL) to Ak-restricted T hybridomas by rat-2 fibroblasts transfected with A alpha k and A beta k (RKK) and RKK cells supertransfected with the mouse invariant chain (RKKI). Only the presentation of the HEL epitope 46-61 was enhanced whereas the presentation of the HEL epitopes 25-43, 34-45, 112-124, and 116-129 was unchanged or even slightly diminished in RKKI cells. The presentation of the epitopes 25-43 and 34-45 was virtually insensitive to the lysosomotropic reagent chloroquine. Brefeldin A (BFA), which inhibits protein egress from the endoplasmic reticulum, blocked the presentation of all epitopes tested in RKKI cells. In contrast, in Ii-negative RKK cells only the presentation of the epitope HEL(46-61) was inhibited by BFA and the presentation of the epitopes 25-43 and 34-45 was only slightly impaired. These findings suggest that Ii may target class II molecules to selected endosomal subcompartments involved in the processing of different peptides derived from an endocytosed antigen. As a result, the enhancement of the class II-restricted presentation in Ii expressing cells appears to be epitope specific rather than antigen specific.

Animals

Intracellular distribution of the MHC class II molecules and the associated invariant chain (Ii) in different cell lines.

Intracellular localization and routing of MHC class II molecules and the associated invariant chain (Ii) were studied using rat-2 cells and HeLa cells stably transfected with the murine class II genes A alpha kA beta k (Ak) alone or supertransfected with human Ii or a truncated delta 20Ii lacking the endosomal sorting signal within Ii. We show that Ii and delta 20Ii are able to bind the class II molecules and replace the highly homologous murine Ii in class II sorting. Expression of transfected Ii or delta 20Ii also result in more efficient transport of class II molecules from the ER. There are, however, cell type specific differences in the intracellular routing of the class II molecules. The endosomal sorting signal within Ii is required to target class II molecules to endosomes in HeLa cells, whereas class II molecules alone enter endosomes in rat-2 cells. Class II molecules cannot direct the associated delta 20Ii to endosomes, suggesting that they follow a direct route to the cell surface and the majority of class II may enter endosomes by internalization. This is also supported by the long lived presence of class II molecules in endosomes after arresting protein transport with cycloheximide or brefeldin A. Class II molecules expressed alone or together with Ii are located in the whole endosomal pathway in rat-2 cells. However, full length Ii is required to target the class II molecules to vesicles that are more chloroquine sensitive than vesicles containing class II molecules alone. Our results thus indicate that Ii is responsible for endosomal sorting of class II molecules in HeLa cells, whereas in rat-2 cells the presence of Ii leads to an altered endosomal distribution.

Animals

Hormonal control of thyrotropin and growth hormone secretion in a human thyrotrope pituitary adenoma studied in vitro.

Pituitary thyrotrope tumours are a rare cause of hyperthyroidism. Prior in vitro studies of these tumours have revealed various patterns of differentiation and secretory activity. We have characterized the histological, biochemical, molecular and physiological features of a thyrotrope adenoma in order to define its origin and autonomy. Histochemical and electron micrograph findings confirmed the diagnosis of a thyrotrope cell adenoma. Immunostaining was positive for TSH and GH in the cytoplasm of the adenoma cells. Tissue extracts contained TSH-IR which co-eluted with authentic hTSH when analysed by gel filtration. Tumour fragments studied in a tissue culture system secreted TSH, alpha-subunit and GH. TRH (30 nmol/l) stimulated TSH and GH secretion. T3 (1.5 nmol/l) inhibited GH release and had no effect on TSH secretion. GnRH (50 nmol/l), dexamethasone (10(-4) mol/l), SRIH (1 mumol/l) and TRH-glycine, a tetrapeptide precursor of TRH, stimulated TSH release. Dexamethasone inhibited GH and alpha-subunit secretion. Stable transcripts for alpha- and beta-subunits of TSH and GH messenger RNAs were detected by molecular hybridization in cytosolic fractions. Immunohistochemistry, in vitro secretory function, and mRNA analysis suggest multidirectional differentiation of the tumour cells. TRH-glycine may have a direct stimulatory effect upon pituitary thyrotropes.

Adenoma

The pathogenesis of idiopathic hypercalciuria: an alternative hypothesis.

Currently, four hypotheses attempt to explain the pathogenesis of idiopathic hypercalciuria. Proposed theories include hypersecretion of parathyroid hormone, hyperabsorption of calcium by the gastrointestinal tract, hyperreabsorption of calcium by the kidney, and hyperexcretion of phosphate by the kidney. These hypotheses are more descriptive than explanatory. A new hypothesis is suggested which encompasses the divergent findings. Idiopathic hypercalciuria may result from hypersecretion of parathyroid hormone which is active at the gastrointestinal and bone target site but is partially defective at its renal site of action.

Calcium

Routine proctosigmoidoscopy: how often?

The cost-yield performance of routine proctosigmoidoscopy can be improved by far fewer examinations limited to the higher-risk patients. Since patients with diminutive polyps are at greater risk but diminutive polyps are rarely malignant and the doubling rate of colon cancer is slow, proctosigmoidoscopic examination of these higher-risk patients every 2 years is safe and more productive. Over 35 percent of those with original negative proctosigmoidoscopy demonstrate a new polyp on a second examination within 6 years. This significant shift into the higher-risk population warrants repeat proctosigmoidoscopy at least every 6 years in those without polyps.

Colonic Diseases